Abstract: Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

Abstract: Provided are compounds of the Formula (I): (I), or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

Abstract: Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.

Abstract: A hybrid power generation plant system and method are disclosed, the system including but not limited to a plurality of diesel engines; an electrical bus switchably attached to the diesel engines, batteries switchably attached to the electrical bus; a tug boat propulsion load attached to the electrical bus; a diesel engine and a battery; a processor the executes a computer program; instructions to determine a current system load serviced by power provided from the hybrid power source; instructions to determine a current operating state for the diesel engine and the battery; instructions to determine a new operating state for the diesel engine and the battery to reduce power consumption servicing the current system load the diesel engine and the battery; and instructions to replace the current operating state for the diesel engine and the battery to the new operating state for the diesel engine and the battery.

Abstract: Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: An automated system for inspecting Petri dishes in which multiple C. elegans nematodes coexist, such that precise mobility characteristics of each individual C. elegans nematode can be extracted. The Petri dish to be monitored is moved in a controlled manner along the X, Y, and Z axes with respect to at least one movable camera that captures a high-resolution sequence of images for each C. elegans nematode, and at least one fixed camera captures a low-resolution sequence of global images that allow the entire Petri dish to be framed. The movable camera is mounted on a movable head in order to move along the Z axis, enabling focusing, and the fixed camera is mounted on a movable trolley, together with the Petri dish, in order to move along the X and Y axes.

Abstract: Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R1, R2, R3, R4 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Abstract: Provided are compounds of Formula (I?): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

Abstract: Provided are compounds of Formula (I?), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: The present disclosure relates to a matrix electromagnetic-suspension system attachable to transportation vehicles. The system comprises a plurality of electromagnetic-suspension modules, each module comprises: an armature; a coil wound on the armature; an adjustable power source connected to the coil, configured to control the intensity of a first magnetic field; and two permanent magnets disposed in contact with the armature, by means of opposite poles, which generate a second magnetic field. The plurality of modules are disposed in a matrix which ensures that the adjacent poles of the permanent magnets of adjacent modules have the same polarity.

Abstract: The present disclosure relates to sulfonamide compounds and pharmaceutically acceptable salts thereof as cardiac sarcomere activators.

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.